VANCOUVER, BRITISH COLUMBIA, January 21, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascal’s…
Read MoreVANCOUVER, BRITISH COLUMBIA, January 19, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer drug discovery and development, has amended the terms of the non-brokered private placement (the “Private Placement”)…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, December 8, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) and SōRSE Technology Corporation (“SōRSE”) have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, November 10, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the appointment of Mark van der Horst to the position of Vice President of Corporate Communications. Mr. van…
Read MoreVANCOUVER, BRITISH COLUMBIA, November 2, 2020 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE: PAS), a biotechnology company that specializes in cancer drug discovery and development, announces a non-brokered private placement (the “Private Placement”) of up to 5,000,000…
Read MoreVANCOUVER, BRITISH COLUMBIA, November 2, 2020 - Pascal Biosciences, Inc. ("Pascal" or the"Company") (TSX VENTURE: PAS), a biotechnology company that specializes in cancer drug discovery and development, wishes to announce that it has re-priced the debt settlement agreements with certain…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 23, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19.…
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 16, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has been invited to present at the International Cannabinoid Derived Pharmaceutical (ICDP) Summit. Today Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in…
Read MoreOur exciting partnership with SōRSE Technology has been featured on an article in Reuters. We invite you to read more here: https://www.reuters.com/article/us-pascal-cancer-sorse/canadas-pascal-biosciences-partners-with-sorse-to-test-cannabis-based-cancer-therapy-idUSKBN2651VC
Read MoreSEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, September 14, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement (the “Agreement”) to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will…
Read More